Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View Item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

Thumbnail
View/Open
Published version (1.982Mb)
Publication Date
2020-04
ICR Author
Dowsett, Mitch
Author
Allison, KH
Hammond, MEH
Dowsett, M
McKernin, SE
Carey, LA
Fitzgibbons, PL
Hayes, DF
Lakhani, SR
Chavez-MacGregor, M
Perlmutter, J
Perou, CM
Regan, MM
Rimm, DL
Symmans, WF
Torlakovic, EE
Varella, L
Viale, G
Weisberg, TF
McShane, LM
Wolff, AC
Type
Journal Article
Metadata
Show full item record
Abstract
<b>Purpose: </b>To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline.<br><br><b>Methods: </b>A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature.<br><br><b>Recommendations: </b>The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines.
URL
https://repository.icr.ac.uk/handle/internal/3500
Collections
  • Breast Cancer Research
  • Molecular Pathology
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
10.1200/jco.19.02309
Research team
Endocrinology
Language
eng
Date accepted
2020-01-09
License start date
2020-04
Citation
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 38 (12), pp. 1346 - 1366

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.